CLARA DAY ON OPERATIONS RESEARCH IN CANCER TREATMENT & OPERATION MANAGEMENT

Transcription

1 CLARA DAY ON OPERATIONS RESEARCH IN CANCER TREATMENT & OPERATION MANAGEMENT November 17, 2010 SPEEDING UP PROGRESS

2 Seven Cancer Research Networks within France Cancer in France Incidence 315,000 / year Mortality 150,000 / year To facilitate and coordinate Cancer research, in particular Translational Research. Coordination by French National Cancer Institute (INCa). Sous l'égide de la Fondation Bullukian P 2

3 CLARA: research network organization European and international dimension P 3

4 CLARA goals Rapid transfer of research to patients Economic development of oncology research Translational Cancer Research Sous l'égide de la Fondation Bullukian P 4

5 CLARA major partners with international leadership position CEA-Leti : Atomic Energy Commission Electronic and Information Technology Laboratory CERN: European Organization for Nuclear Research CRMN: European Center for High Field NMR ELI : European Lymphoma Institute IARC: International Agency for Research on Cancer ELuI: European Lung Institute PARCC-ARA: Support Platform for Clinical Research in Oncology in the inter-region Rhône- Alpes Auvergne WSN: World Sarcoma Network LYON CRMN ELI IARC PARCC WSN GENEVA CERN GRENOBLE CEA-Leti ELuI P 5

6 CLARA major Cancer pathologies with international leadership position 1 st order Lymphoma ELI Pr Coiffier Pr Salles Sarcoma WSN Pr Blay Lung LCEH Pr Brambilla 2 nd order Glioblastoma Hepatocarcinoma Pr Honnorat Pr Berger Pr Trepo, Pr Zoulim, Pr Merle P 6

7 CLARA s whole spectrum of competitive platforms Clinical research Hadrontherapy Bio therapies Cancer prevention Cancer epidemiology Patient bed site Metabolomics Proteomics Genomics - Epigenomics Lab bench Imaging facilities Experimental cancer models Bio informatics Nanotechnologies Pharmacogenomics 50M investment P 7

8 European Observatory of Cancer France Data about Europe P 8

9 CLARA Strengths and Key Features Unique integrated research network focused on oncology in Rhône-Alpes-Auvergne Brings out, evaluates and assists R&D projects involving interdisciplinary experts at the academic, clinical and private companies level Flexible, reactive and significant funding thanks to the support of INCa, local authorities, and European funds making possible both the CLARA Proof of concept programme and CLARA core projects Neutral and independent interface towards private investors and research organisations Sous l'égide de la Fondation Bullukian P 9

10 CLARA auto-analysis STRONG POINTS Significant contribution of CLARA researchers to high-impact journals Five IBiSA national certifications have been granted to CLARA platforms and three major biological resources centres have been certificated CLARA Portfolio of 25 Proof of concept projects ( 32M) based on academic-clinical-industrial cooperation Initiation of first class projects for enhanced visibility and attractiveness of research CLARA mobilises diversified funding resources P 10

11 INCa-funded projects INCa 2009 Activity Report Sous l'égide de la Fondation Bullukian P 11

12 Synopsis of bibliometric analysis Quantitative evolution of publications 140% Progression index (2005 as 100%) 130% 120% 110% World France CLARA 100% year Sous l'égide de la Fondation Bullukian P 12

13 Synopsis of bibliometric analysis Cancéropôles contribution to international visibility Sous l'égide de la Fondation Bullukian P 13

14 CLARA s Proof of Concept programme Growth of CLARA projects portfolio 30 Number of projects Completed with Proof of Concept Completed Ongoing Year Sous l'égide de la Fondation Bullukian P 14

15 CLARA PoC economical impact The projects have generated a variety of economic spillovers. 18 start-ups and SMEs have invested 22 M (versus 10M by CLARA), and 11 companies have reached significant growth milestones : 5 start-ups have been created: idd Biotech, Ecrin Therapeutics, Fluoptics, Netris Pharma and Synthelis, 1 foreign company subsidiary establishment in the region : OncoTherapy Science from Japan, 5 companies raised capital (> 40M) : EDAP TMS, EndoControl Medical, ERYtech Pharma, ImmunID Technologies and Nanobiotix, 4 companies are listed on the stock exchange or trade sale: EDAP TMS, Genome Express, Innate Pharma (IPO) and OPi. Sous l'égide de la Fondation Bullukian P 15

16 CLARA scientific events CLARA organised event co-organised with another Cancéropôle Sous l'égide de la Fondation Bullukian P 16

17 Priorities for Further mobilise its network on two priorities: identification and assistance to projects of academic clinical industrial partnerships in the field of cancer Develop synergies with key regional partners and abroad in the frame of project detection, evaluation, maturing and funding Reinforce communication on its strategy, projects and results, especially on the Cancéropôle CLARA s Proof of Concept programme Gain further financial support from INCa, regional authorities, French programmes and European funds to support ambitious projects P 17

18 Work plan Transverse actions Technological platforms and biological resources centres Support to Clinical Research Proof of concept Axis I: Tumour escape, cell plasticity and targeted therapy Priority axes Axis II: Infections and Cancer Axis III: Nanotechnology, imaging and cancer Axis A: Evaluation, risk perception and cancer prevention Emerging axes Axis B: Environment, nutrition and cancer Axis C: Hadrontherapy and cancer P 18

19 CLARA Ambition for 2014 Expand the CLARA Proof of Concept programme in oncology to other European regions A significant move within its projects from pre-clinical studies to clinical trials An increased participation of CLARA teams to European programmes and ambitious initiatives An acceleration of company creations, development and arrival in the region A broad-spectrum network of experts providing services to oncology research and patients A clear visibility of CLARA s research within the nation and elsewhere in Europe P 19

20 Support to Clinical Research Clinical PARCC-ARA platform PHRC cancer Data management Information Training Support to CLARA s major cancer pathologies European Lymphoma Institute (ELI) World Sarcoma Network (WSN) European Lung Institute (ELuI) In support of Measure 4, Cancer Plan II to stimulate clinical research P 20

21 Project of Evaluation, Risk Perception and Cancer Prevention Links Prevention Primary prevention Identification of risk factors Patients perception of risks Screening Evaluation of screening programmes Determinants of participation to screening programmes Targeted interventions in non-participative population Axis B Axis III Therapeutic management Collective / individual decision-making Quantitative analysis Qualitative analysis Therapeutic management optimisation Homecare Patients education programmes In support of Measure 2, Cancer Plan II to understand through research and reduce inequalities in relation to cancer With support of the interregional Regional Resources Centre for Information, Prevention and Education about Cancers (Hygée centre, St-Etienne) P 21

22 Project of Evaluation, Risk Perception and Cancer Prevention Patients involvement Health inequalities Prevention Education of intermediaries for cancer mass screening in nonprivileged areas Reasons for either participating or not to cancer mass screening Health inequalities for breast and colon cancer screening Therapeutic management Develop a multidisciplinary approach Study the role and consequences of inequalities rather than their description Participate to the development of methods to evaluate interventions to reduce health inequalities Economic study on adherence to clinical practice in sarcoma Determinants of therapeutic management for patients with broncho-pulmonar cancer Evaluation of therapeutic management of hospital vs. home chemotherapy Optimum mapping of various organisational methods according to geographical, epidemiological and demographic situations P 22

23 Thanks to our partners P 23